Clinical trials: Double-blind Randomized Controlled Study
Irritable Bowel Syndrome
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with…
- Trial name
- NCT00486876
- Testing
- Dextofisopam
- Where
- 79 sites in United States
- Volunteers
- 324 people
- Sponsor
- Pharmos
Osteoarthritis
Saline-Controlled Study of nSTRIDE APS for Knee Osteoarthritis
A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with Osteoarthritis (OA) of the knee.
- Trial name
- PROGRESS IV (NCT02905240)
- Testing
- nSTRIDE APS, Saline
- Where
- 27 sites in United States
- Volunteers
- 332 people
- Sponsor
- Zimmer Biomet
Healthy
A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
The purpose of the study is to assess the safety and tolerability of JNJ-77474462 following single subcutaneous (SC) administration to healthy participants of Japanese descent.
- Trial name
- NCT04544826
- Testing
- JNJ-77474462
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pruritus, Atopic Dermatitis
Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis
The purpose of this study is to assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01605708
- Testing
- REGN846
- Where
- 14 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19, Pneumonia
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia
- Trial name
- NCT04459676
- Testing
- Standard of Care (SOC) + ANG-3777
- Where
- 10 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Angion Biomedica Corp
Alopecia Universalis (AU), Alopecia Totalis (AT)
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
- Trial name
- NCT03315689
- Testing
- Vehicle, ATI-50002
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aclaris Therapeutics, Inc.
Healthy
A Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-release Melatonin in Healthy Adults
A study comparing the pharmacokinetics of prolonged-release melatonin versus standard, immediate-release melatonin. Multiple blood draws over a 10-hour period will be analysed to determine the area under the curve, time to peak…
- Trial name
- NCT04067791
- Testing
- Prolonged-Release Melatonin, Immediate-Release Melatonin
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pharmavite LLC
Phenylketonurias
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.
- Trial name
- NCT00104247
- Testing
- sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- BioMarin Pharmaceutical
Infectious Disease, Children, Only
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
The study aims to explore whether prophylactic dietary supplementation with prebiotic inulin-type fructans is able to influence the intestinal microbiota and the frequency of infectious disease episodes in kindergarten children…
- Conditions
- Infectious Disease, Children, Only, Diet Modification
- Trial name
- NCT03241355
- Testing
- prebiotic inulin-type fructan
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Behavioral Variant Frontotemporal Dementia (bvFTD)
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NCT01626378
- Testing
- TRx0237
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- TauRx Therapeutics Ltd
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
OSA - Obstructive Sleep Apnea, Obesity
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
- Trial name
- NCT07434050
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Healthy Volunteers
Phase 1 Study to Determine Safety, Blood PK and Lung Penetration
Multiple center, double-blind, randomized, placebo-controlled study to see if it is safe to give ACHN-490 Injection for 5 consecutive days, to measure plasma pharmacokinetics, and to determine lung penetration of ACHN-490…
- Trial name
- NCT01034774
- Testing
- ACHN-490 Injection
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Achaogen, Inc.
Androgenetic Alopecia, Acne Vulgaris
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and…
- Trial name
- NCT05428449
- Testing
- GT20029 Gel
- Where
- 2 sites in United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
Hypoparathyroidism
Use of NPSP558 in the Treatment of Hypoparathyroidism
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
- Trial name
- REPLACE (NCT00732615)
- Testing
- NPSP558
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 124 people
- Sponsor
- Shire
Sickle Cell Disease
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
- Trial name
- NCT07656415
- Testing
- Mitapivat
- Where
- 5 sites in United States
- Volunteers
- 159 people
- Sponsor
- Agios Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.